A technology-enabled solution combining predictive analytics integrated with real-time commercial services for the life sciences sector.
EVERSANA today launched ACTICS by EVERSANA, a technology-enabled solution to optimize end-to-end commercial success for life science companies. Combining the power of AI-driven predictive analytics with ready-to-deploy, real-time commercial services, ACTICS provides a cloud-based solution for pharmaceutical innovators to optimize actions in the product and patient journeys.
ACTICS is built on a data-mastering platform and cloud-based infrastructure, enabling the ability to combine multiple data sources into a comprehensive and actionable system. Through API-driven automated intelligence and machine learning technology, ACTICS feeds downstream alerts to additional cloud-based infrastructure, such as a client’s CRM system, to create actionable insights.
ACTICS can also solve specific commercial challenges, such as optimizing market access, evidence creation or patient-finding barriers. Clients can leverage select ACTICS capabilities, including project-based data science services, data accessibility and platform licenses for subscription-based modules and platform applications.
For more information, click here.
The State of Mining Data Insights in the Life Sciences Industry – 2024
April 30th 2024A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.